Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics, Inc.'s stock price has fluctuated, declining 59.22% from October 21, 2024, to October 20, 2025, but showing recent increases of 14.46% over three months and 2.94% over six months as of October 26, 2025. Positive clinical data for bexobrutideg (NX-5948), regulatory designations from the EMA and FDA, initiation of the DAYBreak™ clinical trial, a $250.0 million stock offering, and collaborations with Sanofi and Gilead have impacted the stock price.

There is no explicit information indicating demand seasonality for Nurix Therapeutics, Inc.'s products and services. Demand is primarily driven by medical need and disease prevalence, rather than seasonal patterns.

Nurix Therapeutics, Inc., established in 2009, is a clinical-stage biopharmaceutical company focused on developing oral, small molecule therapies for cancer and immune disorders. The company uses its DELigase™ platform to create targeted protein degradation drugs, with a pipeline including bexobrutideg (NX-5948) for CLL and autoimmune indications, zelebrudomide (NX-2127) for B-cell malignancies, and NX-1607 for immuno-oncology. Nurix also has partnered programs with Gilead Sciences, Sanofi, and Pfizer.

Nurix Therapeutics Inc. has its corporate headquarters in San Francisco, California, and R&D centers in Brisbane, California, and The Woodlands, Texas. While primarily based in the U.S., Nurix conducts global clinical trials and has collaborations with international pharmaceutical companies, extending its reach worldwide.

Nurix Therapeutics' brand reputation has been positively influenced by positive clinical data for NX-5948, regulatory designations from the FDA and EMA, and strategic collaborations with companies like Gilead Sciences, Sanofi, and Pfizer. The initiation of pivotal clinical trials also contributes to a strong scientific and corporate reputation.

Nurix Therapeutics, Inc. has a mixed ownership structure including institutional investors, individual insiders, and retail investors. Institutional investors hold a significant portion of the stock, with major holders including Fmr Llc, BlackRock, Inc., and Vanguard Group Inc. Individual insiders own a smaller percentage, with key executives and board members holding significant shares. Retail investors hold the public float.